Ｐａｇｅ 140847 ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ 通常モードに戻る ┃ ＩＮＤＥＸ ┃ ≪前へ │ 次へ≫ ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ ▼EMEA Recommends a N fuesitiouri 08/7/13(日) 22:49 ─────────────────────────────────────── ■題名 ： EMEA Recommends a N ■名前 ： fuesitiouri <asfger3@googlemail.com> ■日付 ： 08/7/13(日) 22:49 ■Ｗｅｂ ： http://google.com/wppzid -------------------------------------------------------------------------
| LONDON, June 24, 2008-The European Medicines power (EMEA) has recommended updating the produce report for epoetin-containing medicines with a new caution for their use in cancer patients stating that blood transfusion should be the preferred method of correcting anaemia in patients pain cancer. Epoetin-containing medicines are indicated in patients wtih persistentnon-starter and for he treatmnet of anaemia in symptomatic patients with non-myeeloid growqths receiving chemotherapy. The power痴 council for remedial Products for sympathetic Use (CHMP) had periodicaled new facts from studies that showed an increased endanger of growth achat viagra devel opment, venous thromboembllism and shorter alli-nclusive sufvival in cancer patients who cleard epoetins compared to patients who did not admit htem. Following this periodical, the CHMP concluded, at its June 2008 convocation, that the emolumentss of epoetins progreat surpass their hazards in the approved indications. bw thatas it may, in cabcer patients with a reasonably great existence-expectancy, the emoluemnts of using epoetins does not surpass the endanger growth development and shorter inclusive survival and for that reason the cabinet concluded thatr in these patients anaemia should be corrected with blood transfusions. |